Research
/
Stock
/
MRNA
M
MRNA
Moderna, Inc. · NASDAQ · Biotech
FY2025
i
Mkt cap 62.7B
158.83
+19.94 +14.36%
close 2026-08-25
i
Overview
Financials
Insider
DCF
Research
/
Stock
/
…
Pulling SEC filings & building this page… the first lookup of a new ticker takes a few seconds, then it's cached.
Mkt Cap
i
62.7B
P/E
i
—
Revenue FY2025
i
1.9B
Gross Margin
i
55.3%
FCF FY2025
i
-2.1B
Net Income
i
-2.8B
52-week range
i
22.36
-8.9% off high
i
174.38
Beta
i
1.33
vs S&P 500 · 1232 common days
Dividend
i
—
no dividend line in the cash flow statement
Price
i
1M
6M
1Y
5Y
i
i
Revenue
i
1.9B
FY2025
i
·
-39.9% YoY
i
i
EBITDA
i
-2.9B
FY2025 · operating + D&A
Free Cash Flow
i
-2.1B
FY2025
i
·
+49.1% YoY
i
i
EPS (diluted)
i
-7.26
FY2025
i
·
+21.8% YoY
i
i
Earnings
i
next est.
Last reported
31 Jul 2026 · 8-K (2.02)
Next report
≈ 16 Oct 2026
Moat & Risks
i
Engine pending
55.3% gross margin (FY2025) — pricing-power signal.
FY2025 10-K ›
Revenue -39.93% YoY to 1.9B (FY2025).
FY2025 10-K ›
Sourced moat / risk brief — generated by the Silkcodex engine (pending run).
Insider activity
i
12 Form 4 · 0 open-market buys vs 5 sells
i
All transactions →
−32M
net open-market
i
2026-08-06
M
Bancel Stephane
· Chief Executive Officer
Option exercise
252,469
5M
2026-08-05
M
Bancel Stephane
· Chief Executive Officer
Option exercise
499,246
10M
2026-08-05
S
Bancel Stephane
· Chief Executive Officer
Sell
147,473
8M
2026-08-05
S
Bancel Stephane
· Chief Executive Officer
Sell
124,838
7M
2026-08-05
S
Bancel Stephane
· Chief Executive Officer
Sell
39,891
2M
Recent filings
8 on file · SEC EDGAR
i
2026-07-31
10-Q
Quarterly report
EDGAR ›
2026-07-31
8-K
Earnings results · Exhibits
EDGAR ›
2026-07-08
8-K
Officer / director change · Reg FD disclosure · Exhibits
EDGAR ›
2026-05-11
8-K
Bylaw amendment · Shareholder vote · Exhibits
EDGAR ›
2026-05-01
10-Q
Quarterly report
EDGAR ›